(Reuters) – AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi’s Dupixent in a late-stage head-to-head study.
Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed.
The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
Atopic dermatitis, a specific form of eczema, is the most common chronic inflammatory skin disease characterized by itchy, dry and inflamed skin.
Rinvoq brought in revenue of $3.97 billion and Dupixent recorded $11.59 billion in global sales in fiscal 2023.
(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Anil D’Silva)
Comments